Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Sichuan Biokin Pharmaceutical Co., Ltd.: A Rising Star in Global Biomedicine

Release time：2025-04-18 21:13:41 Source：DuHao

Tel : +86 028-85183639

Email: net.fei@163.com

Address: 1#, Building 1,No.161, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City, China.

Sichuan Biokin Pharmaceutical Co., Ltd. (also known as Baili Tianheng), a Chengdu-based biomedical enterprise, has emerged as a formidable player in the global pharmaceutical industry, thanks to its relentless focus on innovation and strategic partnerships. The company, founded by Dr. Zhu Yi in 1996, has transitioned from a generic drug manufacturer to a leader in cutting-edge therapies, particularly in oncology.

From Humble Beginnings to Global Ambitions

Dr. Zhu Yi, a visionary with a background in biophysics and enterprise management, established Baili Pharmaceutical (now Baili Tianheng) with a mission to address unmet clinical needs. Initially focusing on generic drugs to build financial stability, the company shifted gears in 2014 to prioritize innovative drug development. This pivot led to the creation of SystImmune, a U.S.-based R&D subsidiary specializing in antibody-drug conjugates (ADCs), a promising class of cancer therapeutics.

Blockbuster Deal with Bristol Myers Squibb

In December 2023, Baili Tianheng announced a landmark collaboration with global pharmaceutical giant Bristol Myers Squibb (BMS) for its flagship ADC drug, BL-B01D1. The deal, valued at up to 8.4 billion, includes an8.4billion,includesan800 million upfront payment and potential milestone payments, marking the largest licensing transaction in China’s innovative drug history. This partnership not only validated Baili Tianheng’s R&D capabilities but also provided critical funding to propel its global expansion.

By March 2024, the initial payment had transformed the company’s financial outlook. Baili Tianheng reported a staggering 936.31% year-on-year revenue increase to 5.823 billion yuan (803 million) and a net profit of 3.708 billion yuan (803million)andanetprofitof3.708billionyuan(511 million), reversing years of losses. Its market capitalization soared past 100 billion yuan ($13.8 billion), cementing Dr. Zhu’s status as the "Richest Man on China’s Sci-Tech Innovation Board."

Innovation at the Core

BL-B01D1, the world’s first EGFR×HER3 dual-antibody ADC in Phase III trials, exemplifies Baili Tianheng’s innovative prowess. The drug targets multiple cancers, including lung, breast, and gastrointestinal tumors, with potential to become a cornerstone of pan-tumor therapy. The company plans to submit new drug applications in China by 2026 and in the U.S. by 2028.

Beyond BL-B01D1, Baili Tianheng boasts a robust pipeline with 14 clinical-stage candidates and over 70 global trials, including 10 Phase III studies in China and 6 in the U.S.

Integrated Manufacturing and Quality Excellence

The company operates four GMP-compliant production bases across China, covering the full drug lifecycle from intermediates to formulations. Its Baili-Bio Base specializes in biologics and ADC production, ensuring scalability for global commercialization.

Mission-Driven Culture

Baili Tianheng’s mission—"to achieve breakthrough therapies for cancer patients worldwide"—reflects its patient-centric ethos. Its core values of integrity, innovation, and global collaboration underpin its ambition to become a multinational pharmaceutical leader.

Looking Ahead

Despite its success, Baili Tianheng remains cautious. The company is pursuing a Hong Kong IPO and a 3.9 billion yuan ($538 million) private placement to fuel R&D and mitigate risks associated with milestone-dependent payments from BMS.

Dr. Zhu Yi’s journey—from a university researcher to the helm of a biotech powerhouse—mirrors China’s rise in global biopharma. As Baili Tianheng strides toward its MNC dream, the world watches closely.

About Sichuan Biokin Pharmaceutical Co., Ltd.

Founded in 1996, Baili Tianheng is a vertically integrated biopharma company with R&D centers in China and the U.S. It specializes in small molecules, biologics, and ADCs, driven by a mission to deliver transformative therapies for cancer patients worldwide.

Duhao Net